Send to

Choose Destination
Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8.

Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.

Author information

Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Str. 40, 60596 Frankfurt, Germany.


Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-alpha, IFN-beta) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-beta and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-beta for the treatment of SARS.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center